Cardinal Health, Inc. Q2 FY2026 earnings call

Management Statement and Operational Highlights

• Strategic Focus: Prioritized strengthening core, expanding in specialty, accelerating other growth businesses, and executing GMPD turnaround. Specialty revenues expected to surpass $50 billion in fiscal 2026.
• Pharmaceutical and Specialty Solutions: Strength in specialty distribution, MSO platforms, and biopharma solutions. Acquisition of Solaris Health completed, with momentum in the market. Investments in technology infrastructure like Vantas HQ e-commerce platform drive customer efficiency.
• GMPD: Continued progress on improvement plan, with focus on growing Cardinal Health brand, enhancing supply chain, and simplifying operations. Products like SmartFlow intermittent pneumatic compression device have positive market response.
• Other Growth Businesses: Nuclear Precision Health Solutions saw over 30% revenue growth in Theranostics. At Home Solutions benefited from ADS integration, creating a platform for chronic condition patients. Optifreight Logistics grew via new customers and expanded utilization of logistics program.

Segment Performance

• Pharmaceutical and Specialty Solutions: Revenue increased 19% to $61 billion, segment profit rose 29% to $687 million. This growth was driven by strong pharmaceutical demand, including ~6 percentage points from GLP-1 sales, and contributions from brand, specialty products, MSO platforms, and generics program.
• GNPD: Revenue grew 3% to $3.3 billion, driven by volume growth from existing customers. Segment profit increased to $37 million from $18 million prior year,受益于现有客户的销量增长和成本优化举措，但受关税不利影响部分抵消。
• Other growth businesses (Nuclear Precision Health Solutions, At Home Solutions, Optifreight Logistics): Revenue jumped 34% to $1.7 billion, driven by strong demand across all three businesses and the acquisition of Advanced Diabetes Supply (ADS). Segment profit soared 52% to $179 million, fueled by strong performance across the businesses and ADS acquisition. The integration of ADS into At Home Solutions progresses well, Nuclear saw over 30% revenue growth in Theranostics, and Optifreight Logistics grew revenues by over 30%.

Guidance

• Raised fiscal year 2026 earnings per share guidance to $10.15 to $10.35, representing year-over-year EPS growth of 23%-26%.
• Pharma segment: Profit guidance raised to 20%-22% growth, with revenue guidance unchanged. Anticipates mid-teens profit growth in the second half, lapping $10 billion of new customers and prior acquisitions.
• GNPD: Revenue guidance updated to 1%-3% growth, profit guidance raised to approximately $150 million, reflecting progress on improvement plan.
• Other growth businesses: Revenue guidance unchanged at 26%-28% growth, profit guidance raised to 33%-35% growth. Will lap ADS acquisition in Q4 and face more difficult comparisons in nuclear business in Q3.
• Effective tax rate: Lowered to 21%-23% from prior outlook of 22%-24%.
• Adjusted free cash flow: Anticipated between $3 billion and $3.5 billion for the year.

Risks

• Market dynamics and fluctuations that could impact revenue and profit.
• Tariff impacts affecting costs and margins.
• Regulatory changes that may disrupt operations or require compliance adjustments.

Question and Answer

Q: Unpack components of profit performance in Pharma Solutions and organic vs inorganic.

A: Jason Hollar and Aaron Alt noted pharma profit driven by specialty, MSOs, generics, with core growth and M&A contributing. Expected mid-teens profit growth in the second half, lapping new customers and prior acquisitions.

Q: Parse apart Other segment performance, especially ADSJ.

A: Jason Hollar and Aaron Alt mentioned strong core growth in Other segment, ADSJ integration going well, with organic investments in each business.

Q: On capital allocation, leverage and potential transactions.

A: Aaron Alt and Jason Hollar discussed disciplined capital allocation, leverage back to target range, and flexibility for acquisitions and share repurchases.

Q: Macro pricing environment impact on guidance.

A: Jason Hollar stated pricing changes factored into guidance, with margins protected through cost structure adjustments.

Q: GLP-1 market impact on revenue/earnings.

A: Jason Hollar said oral contribution slow, GLP-1 revenue growth expected to continue but oral to offset slower injectable growth.

Q: CMS PPE proposal impact on GMPD.

A: Jason Hollar said PPE not a key growth area, but flexible to support domestic sourcing if needed.

Q: Biopharma solutions new business wins.

A: Jason Hollar discussed team capabilities, digitization of platform, and consistent investment in solutions.

Q: Pharma generics program performance.

A: Jason Hollar and Aaron Alt mentioned strong volume in Red Oak generics program, with consistent market dynamics.

Q: GMPD new product development.

A: Jason Hollar said new products focus on existing categories, investing in better products within current categories.

Q: Tech segments growth in Synexis.

A: Aaron Alt mentioned Synexis' growth over 30%, contribution to $1B biopharma services target by 2028.